– USA, MA – Nirogy Therapeutics, a privately-held biotechnology company developing novel small molecules to target cellular transporters, today announced the appointment of Dr. Simon Pedder (Ph.D.) to its Board of Directors as CEO, succeeding founding CEO, Dr. Vincent Sandanayaka who will be transitioning to the role of President and CSO.
“We are delighted to have Simon join us as CEO and on the Board. He brings considerable development know-how to the team at a pivotal time in the Company’s growth, as we prepare to file our first IND for our lead oncology candidate in the next 12 months. Simon’s guidance and expertise in clinical development, regulatory processes, and the commercialization of products in the oncology and autoimmune spaces will be critical as we advance our pipeline and grow the company,” said Board member, Dennis McWilliams.
“It has been a pleasure to lead Nirogy since its inception. I look forward to focusing on the science as CSO and working with Simon to advance our new potential modality of treating cancer and autoimmune diseases,” said Vincent Sandanayaka, Founder, President, and CSO of Nirogy. “Simon brings a wealth of team-building and development experience that will help shepherd our company into clinical development and beyond.”
About Dr. Simon Pedder
Dr. Pedder brings over 30 years of drug development and commercialization experience to Nirogy. Dr. Pedder joins Nirogy from Athenex Pharmaceuticals, where he served as Chief Business and Strategy Officer. Before Athenex, he was President and CEO of Cellectar Biosciences and CEO of Chelsea Therapeutics before that. Earlier in his career, Dr. Pedder held senior leadership roles of increasing responsibility at Hoffmann-LaRoche, including as an Officer of the Company, VP of Oncology Pharma Business, Life Cycle Leader, and Global Project Leader of Pegasys/IFN, and as global Head of the Hepatitis Franchise. Under Dr. Pedder’s leadership, he oversaw the development and commercialization of numerous global brands, such as Tasmar, Copegus, Northera, and Kliseryi Pegasys, which became the standard of care for Hepatitis B and C for over a decade.
“I am thrilled to join Nirogy as it pioneers a new approach to drug development by targeting cellular transporters. The breadth of targets that Nirogy’s platform has the potential to reach is exciting as we look to develop new potential medicines to address significant unmet medical needs for people suffering from cancer and autoimmune diseases,” said Dr. Pedder.
Dr. Pedder began his career as a faculty member in the Department of Pharmacology in the College of Medicine at the University of Saskatchewan, where he obtained his Ph.D. in Clinical Pharmacology. In addition to his Ph.D. in Pharmacology, Simon obtained a Master of Science in Toxicology from Concordia University, a Joint Honors Bachelor of Science in Environmental Studies/Biology from the University of Waterloo, and complete,d the Roche-sponsored Pharmaceutical Executive Management Program at Columbia Business School.
About Nirogy
Nirogy Therapeutics is a biotechnology company based in Boston, MA developing novel small molecules to target cellular transporters. The company is currently advancing a class of small molecules intended to disrupt metabolic and immune mechanisms operative in the tumor microenvironment. Follow-on platform programs are targeting additional disease pathways in oncology as well as autoimmune diseases.
For more information: https://niogytx.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
